FILE 'CAPLUS, MEDLINE' ENTERED AT 13:27:50 ON 29 JUL 2002
L1 9 S ENDOTHELIN AND ACETYLGLUCOSAMINE

L1 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:123595 CAPLUS
DOCUMENT NUMBER: 136:172733
TITLE: .beta.-1-4-N-**Acetylglucosamine** polymers for modulation of vascular structure and/or function
INVENTOR(S): Vournakis, John N.; Finkielsztein, Sergio
PATENT ASSIGNEE(S): Marine Polymer Technologies, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 71 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002019367	A1	20020214	US 2001-781182	20010212

AB The present invention relates to compns. comprising semi-cryst. .beta.-1-4-N-**acetylglucosamine** polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compns. and methods disclosed are useful for stimulating, in a p-GlcNac concn.-dependent manner, **endothelin**-1 release, vasoconstriction, and/or redn. in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-cryst. p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other org. and inorg. contaminants, and whose constituent monosaccharide sugars are attached in a .beta.-1-4 conformation.

L1 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:51660 CAPLUS
DOCUMENT NUMBER: 136:98853
TITLE: Proteins and nucleic acids associated with aging and their detection in identification of tissues undergoing senescence and of senescence modulators
INVENTOR(S): Burmer, Glenna; Pritchard, David; Brown, Joseph P.; Demas, Vasiliki
PATENT ASSIGNEE(S): Lifespan Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004662	A1	20020117	WO 2001-US21361	20010703
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002098495	A1	20020725	US 2001-898730	20010703

PRIORITY APPLN. INFO.: US 2000-216470P P 20000706

AB This invention relates to the discovery of nucleic acids and proteins assocd. with the aging processes, such as cell proliferation and senescence. The identification of these aging-assocd. nucleic acids and

proteins have diagnostic uses in detecting the aging status of a cell population as well as applications for gene therapy and the delaying of the aging process.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:43909 CAPLUS
DOCUMENT NUMBER: 136:303810
TITLE: Vascular Effects of Poly-N-**Acetylglucosamine** in Isolated Rat Aortic Rings
AUTHOR(S): Ikeda, Yasuhiko; Young, Lindon H.; Vournakis, John N.; Lefer, Allan M.
CORPORATE SOURCE: Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA
SOURCE: Journal of Surgical Research (2002), 102(2), 215-220
CODEN: JSGRA2; ISSN: 0022-4804
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Poly-N-**acetylglucosamine** (p-GlcNAc) is a secretion of marine diatoms that is known to be useful in controlling bleeding. As a component of promoting hemostasis, p-GlcNAc is thought to exert vasoconstrictor effects in arteries. The authors examd. vascular effects of p-GlcNAc on isolated aortic rings obtained from Sprague-Dawley rats. The rings were suspended in organ baths and precontracted with U46619, a thromboxane A2 mimetic. The p-GlcNAc produced a concn.-dependent vasoconstriction over the range of 14 to 100 g/mL. At a concn. of 100 .mu.g/mL, p-GlcNAc significantly contracted aortic rings by 133 mg of developed force. Neither a deacetylated deriv. of p-GlcNAc nór a structurally related macromol., chitin, contracted rat aortic rings, indicating a specificity for p-GlcNAc. The vasoconstriction to p-GlcNAc was totally abolished in deendothelialized rat aortic rings, suggesting that an endothelial component is essential to the vasoconstriction. Pretreatment with the **endothelin** ETA receptor antagonist, JKC-301 (0.5 and 1 .mu.M), significantly diminished p-GlcNAc-induced vasoconstriction by 57-61%. However, p-GlcNAc did not significantly diminish nitric oxide release from rat aortic endothelium. These results provide evidence that p-GlcNAc significantly contracts isolated rat aortic rings via an endothelium-dependent mechanism, partly via enhancement of **endothelin**-1 release from endothelial cells. (c) 2002 Academic Press.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:828415 CAPLUS
TITLE: Detection of variations in the DNA methylation profile of genes in the determining the risk of disease
INVENTOR(S): Berlin, Kurt; Piepenbrock, Christian; Olek, Alexander
PATENT ASSIGNEE(S): Epigenomics A.-G., Germany
SOURCE: PCT Int. Appl., 636 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 68
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077373	A2	20011018	WO 2001-XA1486	20010406

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,

ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG

DE 10019058 A1 20011220 DE 2000-10019058 20000406
WO 2001077373 A2 20011018 WO 2001-DE1486 20010406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2000-10019058 A 20000406
WO 2001-DE1486 W 20010406

AB The invention relates to an oligonucleotide kit as probe for the detection of relevant variations in the DNA methylation of a target group of genes. The invention further relates to the use of the same for detg. the gene variant with regard to DNA methylation, a medical device, using an oligonucleotide kit, a method for detg. the methylation state of an individual and a method for the establishment of a model for establishing the probability of onset of a disease state in an individual. Such diseases may be: undesired pharmaceutical side-effects; cancerous diseases; CNS dysfunctions, injuries or diseases; aggressive symptoms or relational disturbances; clin., psychol. and social consequences of brain injury; psychotic disorders and personality disorders; dementia and/or assocd. syndromes; cardiovascular disease, dysfunction and damage; dysfunction, damage or disease of the gastrointestinal tract; dysfunction, damage or disease of the respiratory system; injury, inflammation, infection, immunity and/or anastasis; dysfunction, damage or disease of the body as an abnormal development process; dysfunction, damage or disease of the skin, muscle, connective tissue or bones; endocrine and metabolic dysfunction, damage or disease; headaches or sexual dysfunction. This abstr. record is one of several records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.

L1 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:105315 CAPLUS
DOCUMENT NUMBER: 134:249174
TITLE: Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest
AUTHOR(S): Spahr, Chris S.; Davis, Michael T.; McGinley, Michael D.; Robinson, John H.; Bures, Edward J.; Beierle, Jill; Mort, Jessica; Courchesne, Paul L.; Chen, Kui; Wahl, Robert C.; Yu, Wen; Luethy, Roland; Patterson, Scott D.
CORPORATE SOURCE: Departments of Biochemistry and Genetics, Thousand Oaks, CA, USA
SOURCE: Proteomics (2001), 1(1), 93-107
Published in: Electrophoresis, 22(2)
CODEN: PROTC7; ISSN: 1615-9853
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The proteome of normal male urine from a com. pooled source has been examd. using direct liq. chromatog.-tandem mass spectrometry (LC-MS/MS). The entire urinary protein mixt. was denatured, reduced and enzymically

digested prior to LC-MS/MS anal. using a hybrid-quadrupole time-of-flight mass spectrometer (Q-TOF) to perform data-dependent ion selection and fragmentation. To fragment as many peptides as possible, the mixt. was analyzed four sep. times, with the mass spectrometer selecting ions for fragmentation from a subset of the entire mass range for each run. This approach requires only an autosampler on the HPLC for automation (i.e, unattended operation). Across these four analyses, 1.450 peptide MS/MS spectra were matched to 751 sequences to identify 124 gene products (proteins and translations of expressed sequence tags). Interestingly, the exptl. time for these analyses was less than that required to run a single two-dimensional gel.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:321538 CAPLUS
DOCUMENT NUMBER: 132:352792
TITLE: Pharmaceutical compositions for treatment of cell proliferative disorders containing **endothelin** antagonists and polyacetylglucosamine
INVENTOR(S): Vournakis, John N.; Finkielsztein, Sergio; Pariser, Ernest R.
PATENT ASSIGNEE(S): Marine Polymer Technologies, Inc., USA
SOURCE: U.S., 32 pp., Cont.-in-part of U.S. 5,858,350.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6063911	A	20000516	US 1998-218288	19981222
US 5622834	A	19970422	US 1993-160569	19931201
US 5623064	A	19970422	US 1994-347911	19941201
US 5858350	A	19990112	US 1995-471290	19950606
WO 2000036918	A1	20000629	WO 1999-US30575	19991221
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1139752	A1	20011010	EP 1999-968523	19991221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001003071	A	20010820	NO 2001-3071	20010620

PRIORITY APPLN. INFO.:
US 1993-160569 A2 19931201
US 1994-347911 A2 19941201
US 1995-471290 A2 19950606
US 1998-218288 A 19981222
WO 1999-US30575 W 19991221

AB The present invention relates to methods and compns. comprising at least one **endothelin** antagonist, preferably in combination with a poly-.beta.-1.fwdarw.4-N-**acetylglucosamine** (p-GlcNAc) polysaccharide matrix, for use in the treatment of cancer and other proliferative diseases. The **endothelin** antagonist can be a peptide or non-peptide compd., and the p-GlcNAc matrix of the invention is comprised of a polymer of high mol. wt. whose constituent monosaccharide sugars are attached in a .beta.-1.fwdarw.4 conformation, and which is free of proteins, and substantially free of single amino acids, and other org.

and inorg. contaminants. The compns. and methods of the invention are useful for inhibiting the growth of tumors and other neoplastic cells and/or for inhibiting the metastasis of neoplastic cells in vivo. P-GlcNAc was extd. from Thalassiosira fluviatilis (6.85 mg/L of culture), purified and deacetylated (prepn. given). Efficacy of a mixt. of 2% p-GlcNAc and 3 mg/kg Ro61-0612/001 in melanoma metastases in mice was shown.

REFERENCE COUNT: 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:51732 CAPLUS
DOCUMENT NUMBER: 116:51732
TITLE: Evidence of glycosylated sites on the **endothelin**-1 receptor in Swiss 3T3 cells
AUTHOR(S): Devesly, Pierre; Cade, Christina; Polokoff, Mark A.; Botelho, Lynne H. Parker
CORPORATE SOURCE: Dep. Pharmacol., Berlex Lab., Inc., Cedar Knolls, NJ, 07927, USA
SOURCE: J. Cardiovasc. Pharmacol. (1991), 17(Suppl. 7), S134-S136
CODEN: JCPCDT; ISSN: 0160-2446
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of incubation of intact cells with 6 different lectins on the specific binding of [125I]**endothelin**-1 (ET-1) were detd. in Swiss 3T3 fibroblasts. ET-1 binding was unaffected by pretreatment of cells for 1 h at 37.degree. with Con A, soybean agglutinin, Ulex europaeus agglutinin I, peanut agglutinin, or Galanthus nivalis agglutinin. However, preincubation of cells with 300 .mu.g/mL of wheat germ agglutinin resulted in a 70% decrease in specific binding of ET-1 to cell-surface receptors. The inhibitory effects of wheat germ agglutinin were diminished by brief incubation of lectin-treated cells with 100 mM N-**acetylglucosamine**, a monosaccharide specifically recognized by wheat germ agglutinin. Neither glucose nor mannose had any effect on wheat germ agglutinin-mediated inhibition of the specific binding of ET-1. These results suggest that the ET-1 receptor on 3T3 cells is a glycoprotein that contains one or more N-**acetylglucosamine** residues at or near the ligand binding site.

L1 ANSWER 8 OF 9 MEDLINE
ACCESSION NUMBER: 2002098424 MEDLINE
DOCUMENT NUMBER: 21655424 PubMed ID: 11796021
TITLE: Vascular effects of poly-N-**acetylglucosamine** in isolated rat aortic rings.
AUTHOR: Ikeda Yasuhiko; Young Lindon H; Vournakis John N; Lefer Allan M
CORPORATE SOURCE: Department of Physiology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
CONTRACT NUMBER: HL-07599 (NHLBI)
SOURCE: JOURNAL OF SURGICAL RESEARCH, (2002 Feb) 102 (2) 215-20.
Journal code: 0376340. ISSN: 0022-4804.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200202
ENTRY DATE: Entered STN: 20020207
Last Updated on STN: 20020222
Entered Medline: 20020221

AB BAACKGROUND: Poly-N-**acetylglucosamine** (p-GlcNAc) is a secretion of marine diatoms that is known to be useful in controlling bleeding. As a component of promoting hemostasis, p-GlcNAc is thought to exert vasoconstrictor effects in arteries. The present study was undertaken to

determine whether p-GlcNAc induced a significant vasoconstrictor effect and, if so, what the mechanism of this effect might be. MATERIALS AND METHODS: We examined vascular effects of p-GlcNAc on isolated aortic rings obtained from Sprague-Dawley rats. The rings were suspended in organ baths and precontracted with U46619, a thromboxane A2 mimetic. RESULTS: p-GlcNAc produced a concentration-dependent vasoconstriction over the range of 14 to 100 microg/ml. At a concentration of 100 microg/ml, p-GlcNAc significantly contracted aortic rings by 133 +/- 20 mg of developed force ($P < 0.01$). Neither a deacetylated derivative of p-GlcNAc nor a structurally related macromolecule, chitin, contracted rat aortic rings, indicating a specificity for p-GlcNAc. The vasoconstriction to p-GlcNAc was totally abolished in deendothelialized rat aortic rings, suggesting that an endothelial component is essential to the vasoconstriction. Pretreatment with the **endothelin** ET(A) receptor antagonist, JKC-301 (0.5 and 1 microM), significantly diminished p-GlcNAc-induced vasoconstriction by 57 to 61% ($P < 0.01$). However, p-GlcNAc did not significantly diminish nitric oxide release from rat aortic endothelium. CONCLUSION: These results provide evidence that p-GlcNAc significantly contracts isolated rat aortic rings via an endothelium-dependent mechanism, partly via enhancement of **endothelin**-1 release from endothelial cells.

L1 ANSWER 9 OF 9 MEDLINE
ACCESSION NUMBER: 92219669 MEDLINE
DOCUMENT NUMBER: 92219669 PubMed ID: 1725309
TITLE: Evidence of glycosylated sites on the **endothelin** -1 receptor in Swiss 3T3 cells.
AUTHOR: Devesly P; Cade C; Polokoff M A; Botelho L H
CORPORATE SOURCE: Department of Pharmacology, Berlex Laboratories, Inc., Cedar Knolls, New Jersey.
SOURCE: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, (1991) 17 Suppl 7 S134-6.
Journal code: 7902492. ISSN: 0160-2446.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199205
ENTRY DATE: Entered STN: 19920529
Last Updated on STN: 20020125
Entered Medline: 19920512

AB The effects of incubation of intact cells with six different lectins on the specific binding of [125I]**endothelin**-1 (ET-1) were determined in Swiss 3T3 fibroblasts. ET-1 binding was unaffected by pretreatment of cells for 1 h at 37 degrees C with concanavalin A, soybean agglutinin, Ulex europaeus agglutinin I, peanut agglutinin, or Galanthus nivalis agglutinin. However, preincubation of cells with 300 micrograms/ml of wheat germ agglutinin resulted in a 70% decrease in specific binding of ET-1 to cell-surface receptors. The inhibitory effects of wheat germ agglutinin were diminished by brief incubation of lectin-treated cells with 100 mM N-**acetylglucosamine**, a monosaccharide specifically recognized by wheat germ agglutinin. Neither glucose nor mannose had any effect on wheat germ agglutinin-mediated inhibition of the specific binding of ET-1. These results suggest that the ET-1 receptor on 3T3 cells is a glycoprotein that contains one or more N-**acetylglucosamine** residues at or near the ligand binding site.

=>

See page 8-9 of handout

L2 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
AN 2000:666548 CAPLUS
DN 133:233924
TI Insecticidal **cyclodextrin** inclusion complexes of neem extract
IN Subba Rao, Pillarisetti Venkata; Kumble, Sandeep Prabhu; Annadurai, Ramasamy Sambasivan; Srinivas, Malladi; Rao, Alapati Srinivasa; Ramadoss, Candadai Seshadri
PA India
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA English
Saponin
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000054596	A1	20000921	WO 1999-IN9	19990318
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9936263	A1	20001004	AU 1999-36263	19990318
EP 1191851	A1	20020403	EP 1999-918256	19990318
R: BE, DE, DK, FR, GB, NL, SE				
PRAI WO 1999-IN9	A	19990318		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 2 WPIDS (C) 2002 THOMSON DERWENT
AN 2000-594390 [56] WPIDS
DNC C2000-177553
TI Process for preparing water soluble **cyclodextrin** inclusion complexes of azadirachtin-A gives an insecticidal product with enhanced shelf life.
DC C02
IN ANNADURAI, R S; KUMBLE, S P; RAMADOSS, C S; RAO, A S; SRINIVAS, M; SUBBA RAO, P V
PA (ANNA-I) ANNADURAI R S; (KUMB-I) KUMBLE S P; (RAMA-I) RAMADOSS C S; (RAOA-I) RAO A S; (SRIN-I) SRINIVAS M; (SUBB-I) SUBBARAO P V; (VITT-N) VITTAL MALLYA SCI RES FOUND; (RAOP-I) SUBBA RAO P V
CYC 85

PI WO 2000054596	A1 20000921 (200056)* EN	20p	A01N065-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW			
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW			
AU 9936263	A 20001004 (200101)		A01N065-00
EP 1191851	A1 20020403 (200230) EN		A01N065-00
R: BE DE DK FR GB NL SE			

ADT WO 2000054596 A1 WO 1999-IN9 19990318; AU 9936263 A AU 1999-36263 19990318, WO 1999-IN9 19990318; EP 1191851 A1 EP 1999-918256 19990318, WO 1999-IN9 19990318
FDT AU 9936263 A Based on WO 200054596; EP 1191851 A1 Based on WO 200054596
PRAI WO 1999-IN9 19990318
IC ICM A01N065-00

ICS A01N025-22